Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 13/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.67 |
| ▸ | CDC42 | P60953 | 1/20 | 0.67 |
| ▸ | RAC1 | P63000 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.67 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431128 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL30717241 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL10025981 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL1217681 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL27401798 | 0.98 | AKR1B1 (0.67) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL503391 | 0.93 | AKR1B1 (0.61) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11470486 | 0.90 | AKR1C3 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Naproxen SCHEMBL23753934 | 0.89 | AKR1C3 (0.88) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Ammonia Solution, Strong SCHEMBL11721423 | 0.89 | AKR1C3 (0.67) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL15695558 | 0.89 | UGT2B7 (0.60) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010529-A1 | PRODUCTION OF ENANTIOPURE ALCOHOLS, AMINES AND ACIDS FROM RACEMIC EPOXIDES BY CASCADE BIOTRANSFORMATION INVOLVING EPOXIDE ISOMERIZATION AND DYNAMIC KINETIC RESOLUTION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-01-11 | — | — | WO | disclosed |
| WO-2013028132-A9 | CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-08-22 | — | — | WO | disclosed |
| US-8268865-B2 | Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120165276-A1 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120077976-A1 | CAMPHOR-DERIVED COMPOUNDS, METHOD FOR MANUFACTURING THE SAME, AND APPLICATION THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-03-29 | — | — | US | disclosed |
| US-20120077976-A1 | CAMPHOR-DERIVED COMPOUNDS, METHOD FOR MANUFACTURING THE SAME, AND APPLICATION THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-03-29 | — | — | US | disclosed |
| EP-1045836-B1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1045836-B1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-05 | — | — | EP | disclosed |
| CN-1128874-C | Rhodococcus sp.D12 and its culture method and application | SHANGHAI INST ORGANIC CHEM (CN) | 2003-11-26 | — | — | CN | disclosed |
| US-6284768-B1 | Src family SH2 domain inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-09-04 | — | — | US | disclosed |
| US-6268365-B1 | Src family SH2 domain inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-07-31 | — | — | US | disclosed |
| CN-1291648-A | Rhodococcus sp.D12 and its culture method and application | SHANGHAI INST ORGANIC CHEM (CN) | 2001-04-18 | — | — | CN | disclosed |
| EP-1045836-A1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| US-6054470-A | Src family SH2 domain inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999031066-A1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0314759-A4 | ASYMMETRIC HYDROFORMYLATIONS OF PROCHIRAL OLEFINS TO CHIRAL ALDEHYDES IN HIGH ENANTIOMERIC EXCESS. | UNIV COLORADO STATE RES FOUND (US) | 1990-01-29 | — | — | EP | disclosed |
| EP-0314759-A1 | ASYMMETRIC HYDROFORMYLATIONS OF PROCHIRAL OLEFINS TO CHIRAL ALDEHYDES IN HIGH ENANTIOMERIC EXCESS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1989-05-10 | — | — | EP | disclosed |
| WO-1988008835-A1 | ASYMMETRIC HYDROFORMYLATIONS OF PROCHIRAL OLEFINS TO CHIRAL ALDEHYDES IN HIGH ENANTIOMERIC EXCESS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1988-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077976-A1 | CAMPHOR-DERIVED COMPOUNDS, METHOD FOR MANUFACTURING THE SAME, AND APPLICATION THEREOF | PDE10A, PDE6H, PRKAR2A | AKR1B1 218/4885AKR1C3 77/4885AKR1C2 169/4885 |
| US-20120165276-A1 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, SLC47A1 | AKR1B1 2198/4885AKR1C3 3170/4885AKR1C2 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.